S&P 500   3,120.56 (+0.00%)
DOW   28,013.35 (+0.03%)
QQQ   202.77 (-0.07%)
CGC   14.68 (-4.24%)
BABA   186.23 (+0.40%)
GE   11.38 (-1.22%)
T   39.42 (-0.20%)
ACB   2.40 (-12.09%)
F   8.97 (+0.22%)
DIS   148.22 (+2.45%)
S&P 500   3,120.56 (+0.00%)
DOW   28,013.35 (+0.03%)
QQQ   202.77 (-0.07%)
CGC   14.68 (-4.24%)
BABA   186.23 (+0.40%)
GE   11.38 (-1.22%)
T   39.42 (-0.20%)
ACB   2.40 (-12.09%)
F   8.97 (+0.22%)
DIS   148.22 (+2.45%)
S&P 500   3,120.56 (+0.00%)
DOW   28,013.35 (+0.03%)
QQQ   202.77 (-0.07%)
CGC   14.68 (-4.24%)
BABA   186.23 (+0.40%)
GE   11.38 (-1.22%)
T   39.42 (-0.20%)
ACB   2.40 (-12.09%)
F   8.97 (+0.22%)
DIS   148.22 (+2.45%)
S&P 500   3,120.56 (+0.00%)
DOW   28,013.35 (+0.03%)
QQQ   202.77 (-0.07%)
CGC   14.68 (-4.24%)
BABA   186.23 (+0.40%)
GE   11.38 (-1.22%)
T   39.42 (-0.20%)
ACB   2.40 (-12.09%)
F   8.97 (+0.22%)
DIS   148.22 (+2.45%)
Log in

Champions Oncology Stock Price, Forecast & Analysis (NASDAQ:CSBR)

$5.41
+0.02 (+0.37 %)
(As of 11/18/2019 11:59 AM ET)
Today's Range
$5.41
Now: $5.41
$5.41
50-Day Range
$5.10
MA: $5.65
$6.32
52-Week Range
$4.97
Now: $5.41
$13.24
Volume100 shs
Average Volume23,355 shs
Market Capitalization$62.86 million
P/E Ratio541.00
Dividend YieldN/A
Beta1.15
Champions Oncology, Inc develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides Personalized Oncology Solutions (POS) that assist physicians in developing personalized treatment options for cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CSBR
CUSIPN/A
Phone201-808-8400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$27.07 million
Cash Flow$0.07 per share
Book Value$0.19 per share

Profitability

Net Income$130,000.00

Miscellaneous

Employees92
Market Cap$62.86 million
Next Earnings Date12/16/2019 (Estimated)
OptionableNot Optionable

Receive CSBR News and Ratings via Email

Sign-up to receive the latest news and ratings for CSBR and its competitors with MarketBeat's FREE daily newsletter.


Champions Oncology (NASDAQ:CSBR) Frequently Asked Questions

What is Champions Oncology's stock symbol?

Champions Oncology trades on the NASDAQ under the ticker symbol "CSBR."

How were Champions Oncology's earnings last quarter?

Champions Oncology Inc (NASDAQ:CSBR) released its quarterly earnings results on Monday, September, 16th. The biotechnology company reported ($0.06) EPS for the quarter, missing analysts' consensus estimates of $0.03 by $0.09. The biotechnology company had revenue of $6.74 million for the quarter, compared to analysts' expectations of $7.50 million. Champions Oncology had a negative net margin of 3.61% and a negative return on equity of 48.07%. View Champions Oncology's Earnings History.

When is Champions Oncology's next earnings date?

Champions Oncology is scheduled to release their next quarterly earnings announcement on Monday, December 16th 2019. View Earnings Estimates for Champions Oncology.

What price target have analysts set for CSBR?

4 equities research analysts have issued 1-year target prices for Champions Oncology's shares. Their forecasts range from $9.25 to $17.00. On average, they anticipate Champions Oncology's stock price to reach $13.13 in the next year. This suggests a possible upside of 143.5% from the stock's current price. View Analyst Price Targets for Champions Oncology.

What is the consensus analysts' recommendation for Champions Oncology?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Champions Oncology in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Champions Oncology.

What are Wall Street analysts saying about Champions Oncology stock?

Here are some recent quotes from research analysts about Champions Oncology stock:
  • 1. According to Zacks Investment Research, "Champions Oncology, Inc., formerly known as Champions Biotechnology, Inc., engages in the development of advanced technology solutions to personalize the development and use of oncology drugs. The Company's Tumorgraft Technology Platform is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune deficient mice followed by propagation of the resulting engraftments. This technology can evaluate tumor sensitivity/resistance to various single, combination standard and novel chemotherapy agents. Champions Oncology, Inc. is based in Baltimore, Maryland. " (9/24/2019)
  • 2. National Securities analysts commented, "Low risk way to invest in the development of oncology drugs: Champions Oncology (CSBR) sells products and services to pharmaceutical and biotechnology customers to help them quickly eliminate non-promising drugs, and determine the proper indications, dosage, and patient sub-populations for promising drug candidates. We believe that the company will continue to benefit from the expanding pipeline of oncology drugs.

    Sustained profitability: Champions reported two consecutive profitable quarters in F1Q19 and F2Q19. We believe that CSBR will continue to remain profitable in the second half of F2019 based on revenue growth of 34.1%, a rebound in gross margins to over 50%, and a solid control of operating expenses. In F2020, we project that revenues will grow by 22.7%, and operating margins will reach over 12.3% (compared to 5.3% in FY 2019) resulting in GAAP net income of $3.9 million ($0.27 EPS), up from $1.4 million ($0.10 EPS) in F2019.

    Expanding Cash Flow/Solid Balance Sheet: We believe that higher profitability will translate into cash flow from operations of $1.2 million in F2019 and $5.2 million in F2020. Concurrently, we expect cash will reach $2.3 million at the end of F2019 and $7.7 million at the end of F2020. Further, we anticipate CSBR will continue to remain debt-free and will not fund its growth plans through external financing

    Valuation: We believe that Champions is under-valued based on our price target of $17 a share. A discounted cash flow model would yield a value of $18.00 a share based on a discount rate of 10.8% and a terminal value of $12.5 a share, by our estimates. We assume that the company will start paying taxes in 2024, and will generate free cash flow of over $37 million in F2028. Based on an Enterprise Value to Sales multiple of 6x calendar 2020 revenues of $37.0 million, this would peg shares at a $16.00 valuation. Our $17 price target reflects an average of these two valuation methods. Our multiple reflects a slightly premium to small, fast growing life sciences companies that offer proprietary products and services for the oncology market.
    " (2/27/2019)

Has Champions Oncology been receiving favorable news coverage?

News headlines about CSBR stock have been trending very negative on Monday, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Champions Oncology earned a news impact score of -3.0 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for Champions Oncology.

Are investors shorting Champions Oncology?

Champions Oncology saw a decline in short interest in the month of October. As of October 31st, there was short interest totalling 156,700 shares, a decline of 16.3% from the September 30th total of 187,200 shares. Based on an average daily trading volume, of 32,900 shares, the days-to-cover ratio is presently 4.8 days. Currently, 2.7% of the company's shares are short sold. View Champions Oncology's Current Options Chain.

Who are some of Champions Oncology's key competitors?

What other stocks do shareholders of Champions Oncology own?

Who are Champions Oncology's key executives?

Champions Oncology's management team includes the folowing people:
  • Dr. Ronnie Morris, CEO & Director (Age 53)
  • Mr. David Barry Miller, Chief Financial Officer (Age 50)
  • Dr. Philip P. Breitfeld, Chief Strategy & Innovation Officer and Director (Age 66)
  • Mr. Mark Weinstein, Chief Information Officer
  • Mr. Bruce Ruggeri, Chief Scientific Officer

Who are Champions Oncology's major shareholders?

Champions Oncology's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Cadence Capital Management LLC (2.14%), Tocqueville Asset Management L.P. (1.16%), Ingalls & Snyder LLC (1.14%) and Perkins Capital Management Inc. (0.56%). Company insiders that own Champions Oncology stock include Daniel Newman Mendelson, Joel Ackerman and Ronnie Morris. View Institutional Ownership Trends for Champions Oncology.

Which major investors are selling Champions Oncology stock?

CSBR stock was sold by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc., Cadence Capital Management LLC and Ingalls & Snyder LLC. View Insider Buying and Selling for Champions Oncology.

Which major investors are buying Champions Oncology stock?

CSBR stock was purchased by a variety of institutional investors in the last quarter, including Tocqueville Asset Management L.P.. View Insider Buying and Selling for Champions Oncology.

How do I buy shares of Champions Oncology?

Shares of CSBR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Champions Oncology's stock price today?

One share of CSBR stock can currently be purchased for approximately $5.39.

How big of a company is Champions Oncology?

Champions Oncology has a market capitalization of $62.63 million and generates $27.07 million in revenue each year. The biotechnology company earns $130,000.00 in net income (profit) each year or $0.01 on an earnings per share basis. Champions Oncology employs 92 workers across the globe.View Additional Information About Champions Oncology.

What is Champions Oncology's official website?

The official website for Champions Oncology is http://www.championsoncology.com/.

How can I contact Champions Oncology?

Champions Oncology's mailing address is One University Plaza Suite 307, Hackensack NJ, 07601. The biotechnology company can be reached via phone at 201-808-8400 or via email at [email protected]


MarketBeat Community Rating for Champions Oncology (NASDAQ CSBR)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  130 (Vote Outperform)
Underperform Votes:  169 (Vote Underperform)
Total Votes:  299
MarketBeat's community ratings are surveys of what our community members think about Champions Oncology and other stocks. Vote "Outperform" if you believe CSBR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CSBR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/18/2019 by MarketBeat.com Staff

Featured Article: Penny Stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel